$88 Million is the total value of Asymmetry Capital Management, L.P.'s 30 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 142.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDT | New | MEDTRONIC PLC | $5,772,000 | – | 65,036 | +100.0% | 6.84% | – |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $5,353,000 | +107.4% | 158,810 | +82.2% | 6.35% | +76.4% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $4,806,000 | +15.4% | 25,918 | +2.1% | 5.70% | -1.8% |
| NVRO | Buy | NEVRO CORP | $4,532,000 | +77.0% | 60,893 | +122.9% | 5.37% | +50.6% |
| ACHC | Buy | ACADIA HEALTHCARE CO INC | $4,083,000 | +686.7% | 82,694 | +594.0% | 4.84% | +568.8% |
| GILD | New | GILEAD SCIENCES INC | $4,046,000 | – | 57,157 | +100.0% | 4.80% | – |
| ICPT | New | INTERCEPT PHARMACEUTICALS INC | $3,580,000 | – | 29,570 | +100.0% | 4.24% | – |
| CLVS | Buy | CLOVIS | $3,032,000 | +1386.3% | 32,385 | +912.0% | 3.60% | +1166.2% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $1,909,000 | +131.1% | 166,752 | +320.1% | 2.26% | +96.5% |
| TCMD | New | TACTILE SYSTEMS TECHNOLOGY I | $1,741,000 | – | 60,920 | +100.0% | 2.06% | – |
| DRRX | New | DURECT CORPORATION | $1,636,000 | – | 1,048,473 | +100.0% | 1.94% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $1,565,000 | – | 34,030 | +100.0% | 1.86% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $1,486,000 | – | 12,210 | +100.0% | 1.76% | – |
| NTRA | New | NATERA INC | $693,000 | – | 63,811 | +100.0% | 0.82% | – |
| ATRS | New | ANTARES PHARMA INC | $643,000 | – | 199,655 | +100.0% | 0.76% | – |
| RGNX | Buy | REGENXBIO INC | $275,000 | +15.1% | 13,906 | +12.2% | 0.33% | -2.1% |
| OXFD | New | OXFORD IMMUNOTEC GLOBAL PLC | $273,000 | – | 16,212 | +100.0% | 0.32% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.